• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prolonged double antiplatelet therapy vs association of antiplatelet and low dose of anticoagulant therapy: PEGASUS or COMPASS?

作者信息

Brunetti Natale Daniele, De Gennaro Luisa, Di Biase Matteo, Caldarola Pasquale

机构信息

Department of Medical & Surgical Sciences, University of Foggia, Italy.

Cardiology Department, San Paolo Hospital, Bari, Italy.

出版信息

Int J Cardiol Heart Vasc. 2019 Jul 16;24:100401. doi: 10.1016/j.ijcha.2019.100401. eCollection 2019 Sep.

DOI:10.1016/j.ijcha.2019.100401
PMID:31763434
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6859541/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18e3/6859541/d6aecd8d80f6/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18e3/6859541/d6aecd8d80f6/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18e3/6859541/d6aecd8d80f6/gr1.jpg

相似文献

1
Prolonged double antiplatelet therapy vs association of antiplatelet and low dose of anticoagulant therapy: PEGASUS or COMPASS?延长双重抗血小板治疗与抗血小板和低剂量抗凝治疗联合应用：PEGASUS研究还是COMPASS研究？
Int J Cardiol Heart Vasc. 2019 Jul 16;24:100401. doi: 10.1016/j.ijcha.2019.100401. eCollection 2019 Sep.
2
COMPASS vs PEGASUS approach in a comparative budget impact analysis.在一项比较预算影响分析中COMPASS与PEGASUS方法的对比
Eur J Intern Med. 2021 Jan;83:102-104. doi: 10.1016/j.ejim.2020.10.002. Epub 2020 Oct 10.
3
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.在急性冠脉综合征（GEMINI-ACS-1）中，与低剂量利伐沙班加 P2Y12 抑制相比，加用阿司匹林导致临床显著出血：一项双盲、多中心、随机试验。
Lancet. 2017 May 6;389(10081):1799-1808. doi: 10.1016/S0140-6736(17)30751-1. Epub 2017 Mar 18.
4
Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial.长期替格瑞洛治疗既往心肌梗死患者的成本效益：PEGASUS-TIMI 54 试验结果。
J Am Coll Cardiol. 2017 Aug 1;70(5):527-538. doi: 10.1016/j.jacc.2017.05.063.
5
Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54.既往心肌梗死患者停用 P2Y12 抑制剂后时间与替格瑞洛缺血风险和疗效的关系：来自 PEGASUS-TIMI 54 的见解。
Eur Heart J. 2016 Apr 7;37(14):1133-42. doi: 10.1093/eurheartj/ehv531. Epub 2015 Oct 21.
6
Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.心肌梗死后的长期抗血小板治疗：PEGASUS-TIMI 54研究的启示
Heart. 2016 May 15;102(10):783-9. doi: 10.1136/heartjnl-2015-307858. Epub 2016 Feb 8.
7
[PEGASUS or COMPASS? A guide for a wise clinical choice.].
Recenti Prog Med. 2019 Nov;110(11):518-520. doi: 10.1701/3265.32325.
8
Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial.新型口服抗凝剂与维生素 K 拮抗剂双联治疗伴房颤的支架置入患者：来自 PIONEER AF-PCI 试验的见解。
Circ Cardiovasc Interv. 2019 Nov;12(11):e008160. doi: 10.1161/CIRCINTERVENTIONS.119.008160. Epub 2019 Nov 11.
9
How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland?COMPASS 试验结果如何使波兰的冠心病或外周动脉疾病患者受益？
Kardiol Pol. 2019 Aug 23;77(7-8):661-669. doi: 10.33963/KP.14855. Epub 2019 May 30.
10
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.双重通路抑制在慢性心血管疾病中的协同作用。
Circ Res. 2019 Feb;124(3):416-425. doi: 10.1161/CIRCRESAHA.118.313141.

引用本文的文献

1
Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines.急性冠状动脉综合征患者的长期抗血栓治疗：对现行欧洲心脏病学会指南的批判性评价。
Cardiol J. 2020;27(6):661-676. doi: 10.5603/CJ.a2020.0132. Epub 2020 Oct 19.

本文引用的文献

1
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.根据 COMPASS 试验来看 FAST-MI 2005-2010-2015 注册研究：COMPASS 标准应用于心梗后人群。
Int J Cardiol. 2019 Mar 1;278:7-13. doi: 10.1016/j.ijcard.2018.11.138. Epub 2018 Dec 3.
2
Contemporary management of patients referring to cardiologists one to three years from a myocardial infarction: The EYESHOT Post-MI study.心梗后一至三年就诊心内科患者的当代管理：EYESHOT 心梗后研究。
Int J Cardiol. 2018 Dec 15;273:8-14. doi: 10.1016/j.ijcard.2018.08.055. Epub 2018 Aug 19.
3
Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease.
替格瑞洛用于多支血管病变冠心病患者的动脉血栓事件二级预防。
J Am Coll Cardiol. 2018 Feb 6;71(5):489-496. doi: 10.1016/j.jacc.2017.11.050.
4
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.利伐沙班联合或不联合阿司匹林用于稳定型心血管疾病。
N Engl J Med. 2017 Oct 5;377(14):1319-1330. doi: 10.1056/NEJMoa1709118. Epub 2017 Aug 27.
5
Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial.使用抗凝策略的心血管结局研究（COMPASS）试验的原理、设计及参与者基线特征
Can J Cardiol. 2017 Aug;33(8):1027-1035. doi: 10.1016/j.cjca.2017.06.001. Epub 2017 Jun 8.
6
Implications of the PEGASUS-TIMI 54 trial for US clinical practice.PEGASUS-TIMI 54试验对美国临床实践的启示。
Open Heart. 2017 Apr 21;4(1):e000580. doi: 10.1136/openhrt-2016-000580. eCollection 2017.
7
Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease.替格瑞洛用于外周动脉疾病患者心肌梗死后预防缺血事件。
J Am Coll Cardiol. 2016 Jun 14;67(23):2719-2728. doi: 10.1016/j.jacc.2016.03.524. Epub 2016 Apr 1.
8
Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54.既往心肌梗死患者停用 P2Y12 抑制剂后时间与替格瑞洛缺血风险和疗效的关系：来自 PEGASUS-TIMI 54 的见解。
Eur Heart J. 2016 Apr 7;37(14):1133-42. doi: 10.1093/eurheartj/ehv531. Epub 2015 Oct 21.
9
Long-term use of ticagrelor in patients with prior myocardial infarction.既往心肌梗死患者中长期使用替格瑞洛。
N Engl J Med. 2015 May 7;372(19):1791-800. doi: 10.1056/NEJMoa1500857. Epub 2015 Mar 14.
10
Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial.替格瑞洛对比安慰剂用于阿司匹林-溶栓治疗心肌梗死 54 患者（PEGASUS-TIMI 54 试验）预防心血管事件的设计和原理。
Am Heart J. 2014 Apr;167(4):437-444.e5. doi: 10.1016/j.ahj.2013.12.020. Epub 2014 Jan 6.